SPIMACO ADDWAEIH announces its board's agreement in the meeting held on Wednesday 8161436 corresponding to 632015, for establishing a project within the company's plant in Qassim region allocated for the production of cancer drugs. The initial capital cost of the project reached approximately 200 million which is expected to be completed by (24) months.
The final budget and timetable of the project will be set only after completing the project's engineering studies. The project will be self-financed along with taking advantage of financing opportunities from commercial banks and the industrial development fund. Carrying out this project, SPIMACO ADDWAEIH aims at continuous investment in specialized medication, introducing an advanced industrial technique to Saudi Arabia and activation of its agreement with the Irish Company, EirGen Pharma; which includes an exclusive license, supply along with priority rights to SPIMACO ADDWAEIH to choose from EirGen Pharma's medical cosmetics for cancer treatment to the Middle East, North Africa and Turkey. SPIMACO ADDWAEIH will amend the license and supply agreement into a transport and settlement of the included cosmetics technique upon completion of SPIMACO ADDWAEIH project.

distributed by